首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma
【24h】

Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma

机译:转录组的荟萃分析显示let-7b是不利的预后生物标志物,并预测高度浆液性卵巢癌的分子和临床亚类

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

High-grade serous ovarian carcinoma (HG-SOC) is a heterogeneous, poorly classified, lethal disease that frequently exhibits altered expressions of microRNAs. Let-7 family members are often reported as tumor suppressors; nonetheless, clinicopathological functions and prognostic values of individual let-7 family members have not been addressed in HG-SOC. In our work, we performed an integrative study to investigate the potential roles, clinicopathological functions and prognostic values of let-7 miRNA family in HG-SOC. Using microarray and clinical data of 1,170 HG-SOC patients, we developed novel survival prediction and system biology methods to analyze prognostic values and functional associations of let-7 miRNAs with global transcriptome and clinicopathological factors. We demonstrated that individual let-7 members exhibit diverse evolutionary history and distinct regulatory characteristics. Statistical tests and network analysis suggest that let-7b could act as a global synergistic interactor and master regulator controlling hundreds of protein-coding genes. The elevated expression of let-7b is associated with poor survival rates, which suggests an unfavorable role of let-7b in treatment response for HG-SOC patients. A novel let-7b-defined 36-gene prognostic survival signature outperforms many clinicopathological parameters, and stratifies HG-SOC patients into three high-confidence, reproducible, clinical subclasses: low-, intermediate- and high-risk, with 5-year overall survival rates of 56-71%, 12-29% and 0-10%, respectively. Furthermore, the high-risk and low-risk subclasses exhibit strong mesenchymal and proliferative tumor phenotypes concordant with resistance and sensitivity to primary chemotherapy. Our results have led to identification of promising prognostic markers of HG-SOC, which could provide a rationale for genetic-based stratification of patients and optimization of treatment regimes.
机译:高度浆液性卵巢癌(HG-SOC)是一种异质性,分类不良的致死性疾病,经常表现出microRNA表达的改变。 Let-7家族成员经常被报道为抑癌基因。但是,HG-SOC并未讨论单个let-7家庭成员的临床病理功能和预后价值。在我们的工作中,我们进行了一项综合研究,以调查let-7 miRNA家族在HG-SOC中的潜在作用,临床病理功能和预后价值。我们利用芯片和1,170例HG-SOC患者的临床数据,开发了新颖的生存预测和系统生物学方法,以分析let-7 miRNA与总体转录组和临床病理因素的预后价值和功能关联。我们证明了个人let-7成员表现出不同的进化历史和独特的监管特征。统计测试和网络分析表明,let-7b可以充当全局协同作用的相互作用者和控制数百种蛋白质编码基因的主调节剂。 let-7b的表达升高与存活率低有关,这表明let-7b在HG-SOC患者的治疗反应中起不利作用。一种新颖的let-7b定义的36基因预后生存特征优于许多临床病理参数,并将HG-SOC患者分为三个高可信度,可重现的临床亚类:低,中,高风险,总体为5年存活率分别为56-71%,12-29%和0-10%。此外,高风险和低风险的亚类表现出强的间充质和增生性肿瘤表型,与对原发化疗的耐药性和敏感性相一致。我们的结果导致鉴定出有希望的HG-SOC预后标志物,可为基于基因的患者分层和优化治疗方案提供依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号